Institutional Research Archive

Hedge Fund Letters Archive

Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.

Quarter	Letter Date	Fund Name	QTD	YTD	Tickers	Themes	Quick Take

Home Letters Funds Account

The Ceredex Mid-Cap Value Equity Strategy 2026 Q3 Investor Letter | Buyside Digest

Back to Fund Profile (The Ceredex Mid-Cap Value Equity Strategy)

Primary Source Intelligence • Q3 2026 Letter Analysis

The Ceredex Mid-Cap Value Equity Strategy Quarterly Analysis

Buyside Digest is not affiliated with, and does not endorse, The Ceredex Mid-Cap Value Equity Strategy. This analysis is provided for institutional research purposes only and is not investment advice.

Fund Returns

QTD-8.61%

YTD+13.57%

Annualized+10.44%

Positioning StanceCONSTRUCTIVE

Market CapMid Cap

GeographyUS

Digest Analysis

Quick Take

"Accelerating data center power constraints and a cyclical rebound in biopharma spending provide compelling entry points across overlooked mid-cap equipment providers."

Executive Summary

The Ceredex Mid-Cap Value Equity Strategy Composite returned -8.61% net of fees in the third quarter of 2026, underperforming the Russell Midcap Value Index's return of -1.98%. Year-to-date, the strategy has gained 13.57% net of fees compared to 15.25% for the benchmark. Stock selection in information technology detracted heavily, with AI sentiment reversing sharply following first-half gains, alongside drag from consumer discretionary and financials. Relative performance was supported by strong stock selection across real estate and energy holdings. Macroeconomic conditions remained volatile throughout the quarter as the war involving Iran prompted sharp swings in energy prices and renewed inflation pressures. Global central banks, including the Federal Reserve under new Chairman Warsh, the European Central Bank, and the Bank of Japan, enacted tighter monetary policies, triggering a global bond market selloff. While elevated interest rates weighed on rate-sensitive segments like housing and sparked credit concerns, a resilient U.S. labor market and solid consumer spending continued to provide macroeconomic ballast. Portfolio management actively adjusted exposures during the AI-driven market pullback. The team exited STMicroelectronics due to iPhone launch delays and trimmed Silicon Motion Technology to redeploy into more compelling opportunities, while adding to semiconductor component supplier MKS on weakness. In healthcare, the strategy initiated a new holding in Revvity and expanded Agilent Technologies as biopharma funding indicators improved, while repurchasing Solaris Energy Infrastructure to capture surging AI data center power demand.

Unlock Full Institutional Analysis

Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.

Sign In to Unlock (3 Free Credits)View Pricing Tiers

Institutional Meta Strategy

Meta Strategy Gauges

Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.

Signal Matrix

Market Conviction

65%

CautiousHigh

Moderate (65%)

Position sizing is moderately distributed across holdings, with individual positions capped around 2.0% and the strategy maintaining diversified sector exposure. The manager displays high conviction in specific secular themes by adding to MKS and repurchasing SEI during pullbacks, while showing discipline by completely divesting STMicroelectronics when the core thesis deteriorated.

Growth Outlook

55%

BearishBullish

Neutral (55%)

The outlook balances macro headwinds like sticky inflation, restrictive monetary policy, and bond market selloffs against stable labor markets, solid consumer spending, and strong enterprise AI earnings. The tone is constructive on secular beneficiaries while explicitly cautious on rate-sensitive sectors with weak pricing power.

Risk Appetite

55%

DefensiveAggressive

Balanced (55%)

Capital positioning remains actively tilted toward cyclical recovery themes like life sciences and power equipment, though the manager selectively harvested gains and cut underperformers in rate-sensitive and hardware segments. Risk is calibrated against tighter global credit conditions without retreating aggressively into cash.

Capital Deployment

55%

De-riskingDeploying

Net Neutral (55%)

The strategy rotated capital actively rather than building large defensive cash buffers, reallocating proceeds from sales of STMicroelectronics and Silicon Motion into new positions like Revvity and additions to MKS and Agilent.

Forward Guidance

65%

CautiousExpansionary

Expansionary (65%)

The manager demonstrates a proactive stance toward opportunistic deployment, using pullbacks in semiconductor capital equipment to add to MKS and re-entering SEI to capture AI energy demand. Clear intentions exist to lean into high-quality companies with pricing power as earnings dispersion widens.

Language Signal

52%

BearishBullish

Balanced (52%)

Directional language is evenly balanced between discussing macroeconomic volatility, credit default concerns, and semiconductor selloffs, alongside positive descriptors such as earnings strength, favorable trends, and attractive long-term AI growth potential.

Perceived Risk

68%

Low RiskElevated

Elevated Risk (68%)

Elevated risks are highlighted across several fronts, including geopolitical conflict in the Middle East driving energy volatility, monetary tightening by the Fed under Chairman Warsh, potential credit-default cycles, and uncertainty around AI return on investment.

Opportunity Density

62%

ScarceAbundant

Selective (62%)

Market dislocations generated attractive valuation entry points across mid-cap cyclicals, notably within life sciences and infrastructure equipment, prompting selective buying even as hardware multiple expansion slowed.

Time Horizon

68%

Short-TermLong-Term

Multi-Year (68%)

Portfolio management emphasizes multi-year fundamental thesis horizons, explicitly citing long-term growth opportunities across life sciences reshoring, refining supply constraints, and multi-year AI power infrastructure development.